Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 efgartigimod IV study in AChR-antibody seronegative generalized myasthenia gravis
NL-OMON59376Phase 3Completed
- Sponsor
- argenx
- Start
- Oct 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myasthenia gravis (MG) comparing Efgartigimod IV with Placebo (2 arms). Primary endpoint: MG-ADL total score change from baseline to day 29 in part A. Started Oct 2024; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NL-OMON59376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59376.